Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Clinical trial NCT06284590 · RECRUITING
Trial details
- NCT number
- NCT06284590
- Sponsor
- Philogen S.p.A.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-12
- Primary completion
- 2028-07-01
- Enrollment
- 162
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.